Page 7 - Eric Lenze News Today

In March 2020, Dr. Joseph Vinetz left the contemplative world of his Yale University infectious-disease laboratory and plunged into the covid ward at Yale New Haven Hospital, joining an army of health care workers who struggled to treat the deadly viral disease.

Why haven't more repurposed drugs been pressed into service against Covid?

Group of physician-scientists believes data support authorization for treating COVID-19

Covid-19 experts on which treatments hold up against omicron and which ones to ask a doctor about if you get sick.

New research confirms an earlier study that the antidepressant fluvoxamine prevents some of the most serious complications of COVID-19.

Authors of a newly published study on the use of an antidepressant for COVID-19 claim the drug greatly reduces hospitalizations and mortality. But some experts question whether thats really what the data show.

Fluvoxamine, typically prescribed for depression or OCD, decreased hospitalizations by 66% and reduced mortality by 91% in high-risk COVID-19 outpatients in the phase 3 TOGETHER trial.

This is among the most important findings since the COVID pandemic began

Fluvoxamine: An OCD Drug can Prevent Covid-19 Patients from Hospitalization Last Updated on May 13, 2021 Dozens of COVID patients showed no deterioration in their symptoms when treated with a drug, fluvoxamine, as per a study at the School of Medicines Department of Psychiatry, published in The Journal of the American Medical Association. The outbreak of Coronavirus disease 2019 (COVID-19) has led patients to succumb to serious illnesses and is growing even worse as its second wave takes a tol...

Despite a highlight story on 60 Minutes last month, fluvoxamine, a drug typically used to treat obsessive-compulsive disorder (OCD), is still just a brief mention in the "cytokine inhibitors" section in the For now, it makes sense. Fluvoxamine, a serotonin reuptake inhibitor (SSRI), has shown promise in two smaller studies, but larger trials have not been published yet. Even if the drug becomes a more mainstream treatment for COVID-19, one expert says any demand surge is not expected to resul...